Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 102Neoplasm Metastasis 13Neoplasms 6Triple Negative Breast Neoplasms 5Breast Diseases 5Neoplasms by Site 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Unilateral Breast Neoplasms 2Recurrence 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Breast Neoplasms, Male 2Breast Cancer Female 2Advanced Breast Cancer 2Venous Thromboembolism 1Uterine Cervical Neoplasms 1Thrombocytosis 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Sarcoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Neoplasm, Residual 1Myeloproliferative Disorders 1

Interventions

evening primrose oil 1abemaciclib 1Tamoxifen 1Mammography 1Iodides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fibrocystic Breast Disease × abemaciclib × Breast × Clear all
NCT03979508 2025-11-12

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

Mayo Clinic

Phase 2 Terminated
26 enrolled
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Fibrocystic Breast Disease, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡